Vinblastine
- Generic Name
- Vinblastine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C46H58N4O9
- CAS Number
- 865-21-4
- Unique Ingredient Identifier
- 5V9KLZ54CY
- Background
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
- Indication
For treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma.
- Associated Conditions
- Advanced Soft Tissue Sarcoma, Autoimmune Hemolytic Anemia, Bladder Cancer, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Letterer-Siwe disease, Metastatic Melanoma, Non-Small Cell Lung Cancer (NSCLC), Advanced Alibert-Bazin syndrome, Advanced Testicular cancer, Histiocytic lymphoma, Refractory Breast cancer
- Associated Therapies
- -
Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 50
- Registration Number
- NCT03331341
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-07-28
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Academic and Community Cancer Research United
- Target Recruit Count
- 82
- Registration Number
- NCT03233347
- Locations
- 🇺🇸
University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
FIL Study on ABVD DD-DI as Upfront Therapy in HL.
- Conditions
- Interventions
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 500
- Registration Number
- NCT03159897
- Locations
- 🇮🇹
Ospedale Madonna delle Grazie - Ematologia, Matera, Italy
🇮🇹Presidio ospedaliero "A. TORTORA", Pagani, Italy
🇮🇹Istituto Clinico Humanitas - U.O. Ematologia, Rozzano (MI), Italy
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
- Conditions
- Interventions
- First Posted Date
- 2017-01-27
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 82
- Registration Number
- NCT03033914
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Hackensack Meridian Health, Hackensack, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2016-12-29
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 110
- Registration Number
- NCT03004833
- Locations
- 🇩🇪
University Hospital of Cologne, Cologne, Germany
A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2016-12-01
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Takeda
- Target Recruit Count
- 59
- Registration Number
- NCT02979522
- Locations
- 🇧🇷
ICr - Instituto da Crianca - HCFMUSP, Sao Paulo, Brazil
🇮🇹Ospedale Pediatrico Bambino Gesu,UOC Onco-ematologia, Roma, Italy
🇧🇷Hospital Santa Marcelina, Sao Paulo, Brazil
Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)
- Conditions
- Interventions
- First Posted Date
- 2016-07-21
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- The Hospital for Sick Children
- Target Recruit Count
- 109
- Registration Number
- NCT02840409
- Locations
- 🇨🇦
Montreal Children's Hospital, Montréal, Quebec, Canada
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
🇨🇦Cancer Care Manitoba, Winnipeg, Manitoba, Canada
Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)
- First Posted Date
- 2016-03-17
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 78
- Registration Number
- NCT02710734
- Locations
- 🇺🇸
Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Sidney kimmel Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Washington Cancer Institute at MedStar Washington Hospital Center, Washington, District of Columbia, United States
Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin
- Conditions
- Interventions
- First Posted Date
- 2015-04-10
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 90
- Registration Number
- NCT02414568
- Locations
- 🇫🇷
CHR de Metz-Thionville - Hôpital de Mercy, Metz, France
🇫🇷Hôpital de la Pitié-Salpêtrière, Paris, France
🇫🇷CHRU de Nîmes, Nîmes, France
Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer
- First Posted Date
- 2015-04-09
- Last Posted Date
- 2023-07-10
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 36
- Registration Number
- NCT02412670
- Locations
- 🇺🇸
Illinois CancerCare-Canton, Canton, Illinois, United States
🇺🇸Illinois CancerCare-Carthage, Carthage, Illinois, United States
🇺🇸Illinois CancerCare-Eureka, Eureka, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.